High court ruling speeds up generic biotech drug approval
The court's unanimous ruling Monday means a loss of billions in sales to makers of original versions of biologic drugs.
Pharmaceutical
Articles
FDA asks drugmaker to stop selling its opioid painkiller
Besides contributing to overdoses, abuse of Opana ER was blamed for a 2015 outbreak of HIV and hepatitis C in southern Indiana linked to sharing needles, according to the FDA.
First bellwether trial for ‘low-T’ treatment could have ramifications for Lilly
A set of consolidated lawsuits accuse AbbVie and other makers of testosterone-replacement medicines, including Eli Lilly and Co., of hiding or downplaying their products’ risk for blood clots or other serious injuries.
Drugmakers brace for Trump proposals to tackle U.S. prices
Top pharmaceutical CEOs say they expect President Donald Trump, a frequent critic of industry pricing practices, to take steps soon to address high U.S. drug costs.
Lilly Endowment assets ebb in 2016 as it grants $452.8M
After several years in which the value of its assets swelled, philanthropic giant Lilly Endowment Inc. watched its coffers shrink 12.7 percent in 2016 from about $11.8 billion to $10.3 billion.
Lilly hires ‘powerhouse’ D.C. lobbyist
Leigh Ann Pusey will join Eli Lilly and Co. next month as senior vice president for corporate affairs and communications.
Lilly migraine drug provides relief in late-stage trials
Lilly is in a race with several pharmaceutical firms to develop migraine treatments using an approach known as anti-CGRP and that could create a multibillion-dollar market.
Drug lobby mulling membership reductions amid price scrutiny
The lobby group, Pharmaceutical Research and Manufacturers of America—which counts Eli Lilly and Co. as a member—is proposing that to remain a member, companies will have to spend $200 million a year on research and development.
Marsh Supermarkets closing all in-store pharmacies
The struggling grocery chain told employees Friday morning that it plans to discontinue pharmacy operations and has sold customer prescription files to a national drug store chain.
Express Scripts rebounds as Anthem holds out hope of reconciliation
Express Scripts Holding Co. shares rose Wednesday after health insurer Anthem Inc., its biggest client, said it hasn’t ruled out using the pharmacy benefit manager after their contract expires.
Lilly diabetes drug Jardiance falls short of quarterly sales predictions
Shares in Eli Lilly and Co. stock fell more than 3 percent Tuesday after the Indianapolis-based drugmaker released a quarterly earnings report that showed sales of potential blockbuster drug Jardiance missed expectations by a wide margin.
Express Scripts expects to be dumped by Anthem after 2019
The prescription drug manager said Indianapolis-based Anthem Inc., its biggest customer, doesn’t plan to extend its contract when it expires even though Express Scripts is offering major discounts.
Local life sciences, pharma consultancy acquired by German firm
Safis Solutions LLC, a 15-year-old Indianapolis consulting firm that helps life science companies move their products through the government regulatory process, has been acquired by PharmaLex, the companies announced Monday.
Wall Street punishes Lilly for latest drug setback; analysts grasp for answers
News that federal regulators rejected Lilly’s drug for arthritis sent the stock tumbling more than 5 percent Monday, and sent surprised analysts searching for answers.
Lilly’s rheumatoid arthritis pill rejected by regulators
The drug, which has the proposed brand name Olumiant and is approved for use in Europe, was expected to be a big seller.
FDA issues warning to local doctor for breaking protocol on drug trial
The federal agency says the Indianapolis doctor studying Pfizer’s Chantix last year failed to keep accurate records and used patients who didn’t meet the trial requirements.
Blame game over drug prices escalates with new ad campaign
Broadening its efforts to defuse outrage over skyrocketing prices, the pharmaceutical industry’s lobbying association has started an advertising campaign urging insurers to share with customers more of the benefits of rebates they’ve negotiated.
Eli Lilly chasing psoriasis jackpot with Taltz
Taltz, which hit the market last year, is taking on an armful of older treatments, including creams, lotions, pills and injectables, such as Amgen’s Enbrel and AbbVie’s Humira.
Pharma stocks slide after new tweet from Trump on drug prices
Share of Eli Lilly and Co. and numerous other drug industry stocks fell Tuesday morning after the president sent a tweet promising to lower medicine costs for American people.
As pricing criticism mounts, Lilly, other drugmakers roll out pay for performance
In Lilly’s partnership with Harvard Pilgrim Health Care, the not-for-profit insurer gets additional rebates if fewer patients using Lilly's diabetes treatment Trulicity meet blood sugar goals than expected.